Cited by 1,471Diabetes Management and ResearchDiabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Severe hypoglycemia and risks of vascular events and death

Open access
Zoungas, Sophia, Patel, Anushka, Chalmers, John, de Galan, Bastiaan E., Li, Qiang, Billot, Laurent, Woodward, Mark, Ninomiya, Toshiharu +6 more·2010·New England Journal of Medicine

Abstract

BACKGROUND: Severe hypoglycemia may increase the risk of a poor outcome in patients with type 2 diabetes assigned to an intensive glucose-lowering intervention. We analyzed data from a large study of intensive glucose lowering to explore the relationship between severe hypoglycemia and adverse clinical outcomes. METHODS: We examined the associations between severe hypoglycemia and the risks of macrovascular or microvascular events and death among 11,140 patients with type 2 diabetes, using Cox proportional-hazards models with adjustment for covariates measured at baseline and after randomization. RESULTS: During a median follow-up period of 5 years, 231 patients (2.1%) had at least one severe hypoglycemic episode; 150 had been assigned to intensive glucose control (2.7% of the 5571 patients in that group), and 81 had been assigned to standard glucose control (1.5% of the 5569 patients in that group). The median times from the onset of severe hypoglycemia to the first major macrovascular event, the first major microvascular event, and death were 1.56 years (interquartile range, 0.84 to 2.41), 0.99 years (interquartile range, 0.40 to 2.17), and 1.05 years (interquartile range, 0.34 to 2.41), respectively. During follow-up, severe hypoglycemia was associated with a significant increase in the adjusted risks of major macrovascular events (hazard ratio, 2.88; 95% confidence interval [CI], 2.01 to 4.12), major microvascular events (hazard ratio, 1.81; 95% CI, 1.19 to 2.74), death from a cardiovascular cause (hazard ratio, 2.68; 95% CI, 1.72 to 4.19), and death from any cause (hazard ratio, 2.69; 95% CI, 1.97 to 3.67) (P<0.001 for all comparisons). Similar associations were apparent for a range of nonvascular outcomes, including respiratory, digestive, and skin conditions (P<0.01 for all comparisons). No relationship was found between repeated episodes of severe hypoglycemia and vascular outcomes or death. CONCLUSIONS: Severe hypoglycemia was strongly associated with increased risks of a range of adverse clinical outcomes. It is possible that severe hypoglycemia contributes to adverse outcomes, but these analyses indicate that hypoglycemia is just as likely to be a marker of vulnerability to such events. (Funded by Servier and the National Health and Medical Research Council of Australia; ClinicalTrials.gov number, NCT00145925.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1003795

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The frequency of severe hypoglycemia in the intensive therapy groups of the ACCORD, ADVANCE and VADT trials was 2 to 3 times higher than in standard therapy groups.

    “the frequency of severe hypoglycemia in these trials was 2 to 3 times higher in the intensive therapy groups”

    From Targets for Glycemic Control (2018) · cites this paper as [31]

    Rates of Hypoglycemia over Time (p. 4) reports severe hypoglycemia in 2.7% of ADVANCE’s intensive group versus 1.5% of its standard group—about 1.8 times as frequent. The Discussion (p. 7) also describes a higher rate with intensive treatment in ACCORD, but our copy does not establish a two- to threefold difference across ACCORD, ADVANCE, and VADT. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • In people with type 2 diabetes and established or very high risk for cardiovascular disease, there is a clear association between increased mortality and severe hypoglycemia and symptomatic hypoglycemia.

    “In people with type 2 diabetes and established, or very high risk for, cardiovascular disease (CVD), there is a clear association between an increased mortality and severe hypoglycemia (62,63) and symptomatic hypoglycemia (64).”

    From Hypoglycemia (2018) · cites this paper as [63]

    The Discussion (p. 6) clearly reports an association between severe hypoglycemia and increased mortality. But the Study Population section (p. 3) includes patients with microvascular disease or just one other cardiovascular risk factor, so it does not establish that all participants had established CVD or were at very high CVD risk. The symptomatic-hypoglycemia part is attributed to citation 64, not this paper. (LLM, conf=0.82)

    Experimental — accuracy not yet measured
  • Exposure to severe hypoglycemia is strongly associated with adverse outcomes, including death, in post hoc analyses of trials of strict glycemic control.

    “Post hoc analysis of clinical trials examining the effects of strict glycemic control on cardiovascular outcomes showed that exposure to severe hypoglycemia was strongly associated with a range of adverse outcomes, including death (2, 3).”
  • In ADVANCE, where rates of hypoglycemia were low, a similar pattern of association between severe hypoglycemia and mortality was found.

    “In ADVANCE, where rates of hypoglycemia were low, a similar pattern was found (47).”
  • Higher mortality was reported in participants with 1 or more episodes of severe hypoglycemia in the ACCORD, ADVANCE and VADT trials, irrespective of treatment arms.

    “a higher mortality was reported in participants with 1 or more episodes of severe hypoglycemia in the ACCORD (30), ADVANCE (31) and VADT trials (25), irrespective of the different treatment arms in which individual participants were allocated.”

    From Targets for Glycemic Control (2018) · cites this paper as [31]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. [8]8. Diabetes Trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 2009;53:298-304.
  2. [16]16. Therneau TM, Grambsch PM. Modelling survival data: extending the Cox model. New York: Springer, 2000.

Cited by

Sorted by citations

Authors
Zoungas, S., Patel, A., Chalmers, J., de Galan, B. E., Li, Q., Billot, L., Woodward, M., Ninomiya, T., Neal, B., MacMahon, S., Grobbee, D. E., Kengne, A. P., Marre, M., & Heller, S.
Affiliations
  • The University of Sydney (AU)
  • University Medical Center Utrecht (NL)
  • Hôpital Bichat-Claude-Bernard (FR)
  • National Health Service (GB)
Venue
New England Journal of Medicine
Published
2010-10-07
Volume
363
Issue
15
Pages
1410-1418
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2097995302
Cited by
1,471
References
31
Citations by year
2026: 33 · 2025: 49 · 2024: 64 · 2023: 60 · 2022: 66 · 2021: 103 · 2020: 119 · 2019: 99 · 2018: 113 · 2017: 103 · 2016: 107 · 2015: 147 · 2014: 106 · 2013: 98 · 2012: 103
FWCI
71.78
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Radboud Repository (Radboud University) (submittedVersion)
  • Radboud Repository (Radboud University) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
severe hypoglycemia, type 2 diabetes, tight glycemic control, macrovascular events, cardiovascular mortality, all-cause mortality, adverse clinical outcomes, diabetes complications, UKPDS
MeSH terms
Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Gliclazide, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Risk Factors, Vascular Diseases, Proportional Hazards Models, Microvessels

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review